The study aims to provide the pharmacokinetics profiles of single- and double-dose icodextrin in patients on peritoneal dialysis (PD). It may expand the available knowledge of the clinical pharmacology of icodextrin following its intraperitoneal administration and fills the gaps in our understanding of the fate of icodextrin and the metabolic consequences of icodextrin and its metabolites.

开始日期2024-08-15

申办/合作机构

北京大学第一医院

NCT06492031

/ RecruitingN/A

Effectiveness and Safety of Icodextrin Peritoneal Dialysis Solution (Extraneal®) for Long Dwell Exchange in Peritoneal Dialysis in Patients With Chronic Renal Failure: a Multicenter, Ambispective Cohort, Observational, Real-world Study

The purpose of this study is to evaluate the effectiveness and safety of icodextrin and glucose peritoneal dialysis (PD) solutions for the long dwell exchange in PD patients with continuous ambulatory peritoneal dialysis (CAPD), and to describe medical resource utilization in patients with PD on icodextrin.

开始日期2024-06-28

申办/合作机构

Baxter Healthcare Ltd

NCT05943470

/ Not yet recruiting临床4期IIT

The Difference Between Daily and Alternative Day Use of Icodextrin in Peritoneal Dialysis

Volume overload is an important cause of technical failure in peritoneal dialysis patients. Icodextrin can provide continuous ultrafiltration, which provides a new option for peritoneal dialysis patients.
However, icodextrin metabolites are known to accumulate to some extent in the body, resulting in less ultrafiltration with long-term icodextrin use comparing with newly use.
Therefore, the investigator hypothesized that a single dose of icodextrin would produce more ultrafiltration volume with the use of icodextrin dialysate on alternate days than with the use of icodextrin dialysate on daily uses.

开始日期2023-08-01

申办/合作机构

上海交通大学医学院附属仁济医院

100 项与艾考糊精相关的临床结果

登录后查看更多信息

100 项与艾考糊精相关的转化医学

登录后查看更多信息

100 项与艾考糊精相关的专利（医药）

登录后查看更多信息

601

项与艾考糊精相关的文献（医药）

2025-01-01·Kidney Medicine

Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal

Article

作者: Crosbie, Ian ; Testani, Jeffrey M ; Mendoza-Zavala, Genaro H ; Asher, Jennifer L ; Ramos-Mastache, Daniela ; Rao, Veena S ; Borges-Vela, Julian A ; Ivey-Miranda, Juan B ; Revilla-Monsalve, Cristina ; Cigarroa-Lopez, Jose A ; Moreno-Villagomez, Julieta ; Turner, Jeffrey M ; Silva-Rueda, Rogelio I ; McIntyre, Christopher ; Finkelstein, Fredrick ; Cox, Zachary L ; Goedje, Oliver ; Maulion, Christopher

Rationale & ObjectivePeritoneal dialysis (PD) solutions provide both clearance of uremic toxins and sodium and water. An intraperitoneal (IP) solution of icodextrin and glucose designed without the requirement for uremic toxin clearance could provide substantially greater sodium and water removal than PD solutions.Study DesignWe examined varying concentrations of icodextrin and dextrose IP solutions in rats. We evaluated a 30% icodextrin and 10% dextrose IP solution in animals and humans.ParticipantsSmall and large animal models, and humans (N = 10) with kidney failure.Exposure30% icodextrin and 10% dextrose IP solution.OutcomesWe evaluated ultrafiltration (UF), sodium removal, and peritoneal health in animals. We evaluated safety, tolerability, and efficacy in humans.ResultsIn rats, increasing concentrations of icodextrin and dextrose IP solutions, up to 30% icodextrin and 10% dextrose, produced progressively greater UF (P < 0.001). In sheep treated with 30% icodextrin and 10% dextrose, the mean UF was ∼3.5-fold greater (1.77 ± 0.22 L vs 0.47 ± 0.34 L; P = 0.005) and the mean sodium removal was ∼4-fold greater (7.07 ± 0.72 g vs 1.78 ± 1.27 g; P = 0.003) compared with commercially available 7.5% icodextrin PD solution. Long-term exposure of mice (30 days) and sheep (30-45 days) to a 30% icodextrin and 10% dextrose IP solution resulted in no significant structural tissue changes compared with the control 4.25% commercially available PD solution. In humans, a 24-hour dwell of a 30% icodextrin and 10% dextrose IP solution resulted in median net UF of 2,498 mL (IQR, 2,249-2,768), and median sodium removal of 387 mmol (IQR, 372-434 mmol). No serious adverse events occurred.LimitationsThe long-term safety with chronic therapy and the efficacy in patients without kidney failure were not established and require future studies.ConclusionsA 30% icodextrin and 10% dextrose IP solution provides more efficient UF and sodium removal than traditional PD solutions. The promising inhuman safety and efficacy results warrant future investigation as a sodium removal therapy in patients with edematous disorders such as heart failure.Clinical Trial RegistrationNCT05780086.SummaryWe aimed to design a novel intraperitoneal solution designed for optimal sodium and water removal. A sodium-free 30% icodextrin and 10% dextrose intraperitoneal solution was evaluated in animal models and humans to determine the safety and efficacy. A 30% icodextrin and 10% dextrose solution provides more efficient sodium and water removal than traditional peritoneal dialysis solutions. The promising inhuman safety and efficacy results warrant future investigation as a sodium removal therapy in patients with edematous disorders such as heart failure.

2024-12-01·Behaviour Research and Therapy

Augmented Depression Therapy for young adults: A mixed methods randomised multiple baseline case series evaluation

Article

作者: Carson, James ; Loades, Maria ; Wright, Kim ; Dunn, Barnaby D ; Dunn, Barnaby D. ; Demetriou, Kalliopi ; Barlow, Gemma

Augmented Depression Therapy (ADepT) is an individual psychotherapy for depression, which has been shown to be effective in the general adult population. A randomised multiple baseline case series evaluated the feasibility, acceptability, and effectiveness of ADepT in young adults (aged 20-24). Eleven depressed young adults were recruited from a UK university wellbeing service to receive ADepT during the COVID-19 pandemic, with outcomes evaluated relative to pre-specified continuation targets. All participants received a minimum adequate treatment dose (>60% target); 89% judged ADepT as acceptable and satisfactory and would recommend it to others (>60% target); only 9% showed reliable deterioration for depression or wellbeing (meeting <30% target); and there were no trial- or treatment-related serious adverse events. Qualitative interviews revealed most participants were satisfied with and experienced benefits from ADepT. At post-treatment, reliable improvement was shown by 33% of participants for depression and 67% of participants for wellbeing (not meeting target of both >60%), with medium effect size improvements for depression (g = 0.78) and large effect size improvement for wellbeing (g = 0.93; not meeting target of both >0.80). ADepT is feasible, acceptable, and safe in young adults but may require modification to maximise effectiveness. Further research outside of the COVID-19 pandemic is warranted.

2024-11-18·Einstein (São Paulo)

Icodextrin versus Glucose 2.5% on markers of hypervolemia and survival of patients undergoing automated peritoneal dialysis with an unplanned start: a randomized controlled trial

Article

作者: Alves, Camila Albuquerque ; Mendes, Marcela Lara ; Ponce, Daniela ; Dias, Dayana Bitencourt ; Banin, Vanessa Burgugi ; Moraes, Thyago Proença de ; Azevedo, Leonardo Sotello ; Silva, Maryanne Zilli Canedo

OBJECTIVEThe efficacy of icodextrin versus glucose patients undergoing peritoneal dialysis remains unclear. The study was designed to compare the effects of once-daily long-dwell icodextrin versus glucose on markers of hypervolemia and survival among patients with kidney failure undergoing an unplanned initiation of automated peritoneal dialysis.METHODSThis was a randomized, non-blinded, and prospective controlled study. Prevalent and stable patients undergoing automated peritoneal dialysis with a recent peritoneal equilibration test showing a dialysate/plasma creatinine of >0.50 were randomized to receive either 7.5% icodextrin or 2.5% glucose solution. Patients were evaluated at baseline (one month after the start of peritoneal dialysis), 3 months, and 6 months after inclusion. The peritoneal dialysis solution was used for at least 3 months, with a follow-up period of 24 months.RESULTSThirty patients were enrolled. There were no baseline differences between the groups. During the study period, patients in the Icodextrin Group showed improvements in the phase angle and ultrafiltration, whereas there were no changes in the Glucose Group. Additionally, extracellular water was significantly lower in the Icodextrin Group at the end of the study than at baseline. No statistical differences between the two groups were observed in urine volume, ultrafiltration, extracellular water, phase angle, renal creatinine clearance, use of diuretics and antihypertensives, or blood pressure. During the 24-month follow-up, the number of events related to overall mortality was seven (Icodextrin Group, n=4; Glucose Group, n=3), with no difference between the groups for this outcome or technique survival.CONCLUSIONIcodextrin significantly improved ultrafiltration, extracellular water, and phase angle at the end of the study compared to baseline in patients on the urgent start of automated peritoneal dialysis.REGISTRY OF CLINICAL TRIALS(www.ctri.nic.in) under the number RBR-97z4wh6.

项与艾考糊精相关的新闻（医药）

2025-01-19

·信狐药迅

恒瑞PCSK9抑制剂自研降脂新药瑞卡西单抗、石药降糖药普卢格列汀获批上市| 新获批(1.13-1.19）

每周药品注册获批数据，分门别类呈现，一目了然。(1.13-1.19）新药上市申请药品名称企业注册分类受理号普卢格列汀片石药集团欧意药业有限公司1CXHS2300048赛沃替尼片和记黄埔医药(上海)有限公司2.4CXHS2400022赛沃替尼片和记黄埔医药(上海)有限公司2.4CXHS2400021注射用瑞卡西单抗广东恒瑞医药有限公司1CXSS2300046 新药临床申请药品名称企业注册分类受理号SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401166SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401165SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401164CVI-2742胶囊西威埃医药技术(上海)有限公司1CXHL2401191CVI-2742胶囊西威埃医药技术(上海)有限公司1CXHL2401190DF-003胶囊上海药苑生物科技有限公司1CXHL2401186DF-003胶囊上海药苑生物科技有限公司1CXHL2401185DF-003胶囊上海药苑生物科技有限公司1CXHL2401184QLS1304片齐鲁制药有限公司1CXHL2401194QLS1304片齐鲁制药有限公司1CXHL2401195QLS1304片齐鲁制药有限公司1CXHL2401196ASN-3186胶囊上海亚虹医药科技有限公司1CXHL2401204NSP-1047A片诺沃斯达药业(上海)有限公司1CXHL2401210NSP-1047A片诺沃斯达药业(上海)有限公司1CXHL2401209GH56胶囊勤浩医药(苏州)有限公司1CXHL2401208GH56胶囊勤浩医药(苏州)有限公司1CXHL2401207GH56胶囊勤浩医药(苏州)有限公司1CXHL2401206ASN-3186胶囊上海亚虹医药科技有限公司1CXHL2401205Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401221Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401220Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401219达希替尼片轩竹生物科技股份有限公司1CXHL2401216达希替尼片轩竹生物科技股份有限公司1CXHL2401215Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2401222PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2401226PLB1004胶囊鞍石药业(宁波)有限责任公司1CXHL2401225ANS014004片北京鞍石生物科技股份有限公司1CXHL2401224ANS014004片北京鞍石生物科技股份有限公司1CXHL2401223AZD0022阿斯利康全球研发(中国)有限公司1CXHL2401229AZD0022阿斯利康全球研发(中国)有限公司1CXHL2401228ICP-248片北京诺诚健华医药科技有限公司1CXHL2401217盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1;2.4CXHL2401161盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1;2.4CXHL2401159HQ2216注射液百诚医药(珠海横琴)有限公司2.2CXHL2401154注射用艾博韦泰前沿生物药业(南京)股份有限公司2.4CXHL2401176甲磺酸伏美替尼片上海艾力斯医药科技股份有限公司2.4CXHL2401238RGL-2201注射液上海瑞宏迪医药有限公司1CXSL2400756GenSci120注射液长春金赛药业有限责任公司1CXSL2400763GenSci120注射液长春金赛药业有限责任公司1CXSL2400765IBI3014信达生物制药(苏州)有限公司1CXSL2400768注射用KY-0301科弈(浙江)药业科技有限公司1CXSL2400767 仿制药申请药品名称企业注册分类受理号羧甲司坦口服溶液海南斯达制药有限公司3CYHS2300946奥美拉唑碳酸氢钠干混悬剂湖北邦泽医药有限公司3CYHS2301623氨氯地平贝那普利胶囊河北龙海药业有限公司3CYHS2301852二羟丙茶碱注射液河北千康医药科技有限责任公司3CYHS2302021帕拉米韦注射液长春澜江医药科技有限公司3CYHS2302932盐酸右哌甲酯缓释胶囊河南中帅药业有限公司3CYHS2303628普瑞巴林口服溶液常州四药制药有限公司3CYHS2301334氨溴特罗口服溶液南京创迪生物技术有限公司3CYHS2302950吡拉西坦注射液西安达莫制药有限公司3CYHS2400403磷酸奥司他韦胶囊植恩生物技术股份有限公司4CYHS2400901磷酸奥司他韦胶囊福建省闽东力捷迅药业股份有限公司4CYHS2400923托吡酯片海南日中天制药有限公司4CYHS2301074注射用两性霉素B脂质体江西艾施特制药有限公司4CYHS2301518注射用替考拉宁重庆药友制药有限责任公司4CYHS2301539复方甘草酸苷片东阳祥昇医药科技有限公司4CYHS2301720甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301719甲磺酸仑伐替尼胶囊吉林敖东洮南药业股份有限公司4CYHS2301718地诺孕素片南通联亚药业股份有限公司4CYHS2301847硫酸特布他林雾化吸入用溶液浙江金华康恩贝生物制药有限公司4CYHS2301885钆喷酸葡胺注射液四川国瑞药业有限责任公司4CYHS2301898间苯三酚注射液江苏悦兴药业有限公司4CYHS2302047非那雄胺片乐泰药业有限公司4CYHS2302057非那雄胺片乐泰药业有限公司4CYHS2302056西格列汀二甲双胍片(II)江苏康缘药业股份有限公司4CYHS2302127乳果糖口服溶液安徽美来药业股份有限公司4CYHS2302196吸入用异丙托溴铵溶液浙江金华康恩贝生物制药有限公司4CYHS2302237盐酸莫西沙星片河北天成药业股份有限公司4CYHS2302521复方氨基酸注射液(18AA-IX)四川科伦药业股份有限公司4CYHS2302546马来酸阿伐曲泊帕片瑞阳制药股份有限公司4CYHS2302556盐酸氮斯汀滴眼液浙江视方极医药科技有限公司4CYHS2302677甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302693甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302692甲苯磺酸艾多沙班片齐鲁制药有限公司4CYHS2302691地夸磷索钠滴眼液山东诺明康药物研究院有限公司4CYHS2302729马来酸咪达唑仑片宜昌人福药业有限责任公司4CYHS2302782氯雷他定糖浆南通广承制药有限公司4CYHS2302830伊布替尼胶囊江西科睿药业有限公司4CYHS2302871玛巴洛沙韦片郑州泰丰制药有限公司4CYHS2302877马来酸阿伐曲泊帕片湖南明瑞制药股份有限公司4CYHS2302991甲钴胺注射液广州一品红制药有限公司4CYHS2303000达比加群酯胶囊浙江诺得药业有限公司4CYHS2303164达比加群酯胶囊浙江诺得药业有限公司4CYHS2303163达比加群酯胶囊浙江诺得药业有限公司4CYHS2303162苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303193苯磺酸氨氯地平片广州一品红制药有限公司4CYHS2303192盐酸氮斯汀滴眼液浙江视方极医药科技有限公司4CYHS2303213沙库巴曲缬沙坦钠片江苏德源药业股份有限公司4CYHS2303296注射用紫杉醇(白蛋白结合型)河北天成药业股份有限公司4CYHS2303294硫酸羟氯喹片福建广生堂药业股份有限公司4CYHS2303516酒石酸溴莫尼定滴眼液广东众生药业股份有限公司4CYHS2303512贝前列素钠片江西科睿药业有限公司4CYHS2303507尼可地尔片浙江赛默制药有限公司4CYHS2303503罗沙司他胶囊哈尔滨三联药业股份有限公司4CYHS2302026罗沙司他胶囊哈尔滨三联药业股份有限公司4CYHS2302025罗沙司他胶囊广州康臣药业有限公司4CYHS2302564罗沙司他胶囊北京福元医药股份有限公司4CYHS2302942罗沙司他胶囊北京福元医药股份有限公司4CYHS2302941富马酸福莫特罗吸入溶液长风药业股份有限公司4CYHS2302621富马酸福莫特罗吸入溶液南京力成药业有限公司4CYHS2303034盐酸伊托必利片裕松源药业有限公司4CYHS2404103氯沙坦钾氢氯噻嗪片裕松源药业有限公司4CYHS2404128奥美沙坦酯氨氯地平片裕松源药业有限公司4CYHS2404050吸入用布地奈德混悬液浙江高跖医药科技股份有限公司4CYHS2302457玻璃酸钠滴眼液辅必成(上海)医药科技有限公司4CYHS2400844艾考糊精腹膜透析液芜湖道润药业有限责任公司4CYHS2401530贝伐珠单抗注射液上海生物制品研究所有限责任公司3.3CXSS2300058重组人II型肿瘤坏死因子受体-抗体融合蛋白注射液海正生物制药有限公司3.4CXSS2300056重组人II型肿瘤坏死因子受体-抗体融合蛋白注射液海正生物制药有限公司3.4CXSS2300055德谷胰岛素利拉鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400772 进口申请药品名称企业注册分类受理号厄达替尼片Janssen Biotech, Inc.5.1JXHS2300124厄达替尼片Janssen Biotech, Inc.5.1JXHS2300123厄达替尼片Janssen Biotech, Inc.5.1JXHS2300125帕博利珠单抗注射液Merck Sharp & Dohme LLC3.1JXSS2400034艾沙妥昔单抗注射液Sanofi Winthrop Industrie3.1JXSS2300090艾沙妥昔单抗注射液Sanofi Winthrop Industrie3.1JXSS2300091奥拉帕利片Natco Pharma Limited5.2JYHS2300075奥拉帕利片Natco Pharma Limited5.2JYHS2300074MRG-001注射液MEDREGEN, LLC2.3;2.4JXHL2400259Vorasidenib片Institut de Recherches Internationales Servier2.4JXHL2400265Vorasidenib片Institut de Recherches Internationales Servier2.4JXHL240026613价肺炎球菌多糖结合疫苗Pfizer Europe MA EEIG3.1JXSL2400209Itepekimab注射液Sanofi-Aventis Recherche & Developpement1JXSL2400200注射用德曲妥珠单抗Daiichi Sankyo, Inc.2.2JXSL2400217 中药相关申请药品名称企业注册分类受理号苦丁茶总皂苷提取物华医神农(珠海)医药科技有限公司1.2CXZL2400069苦丁茶皂苷片华医神农(珠海)医药科技有限公司1.2CXZL2400068 注：橙色字体部分结论为不批准或收到通知件；

申请上市上市批准临床申请

2025-01-19

·药通社

同一日下发，3个品种或未被批准？

统计每周仿制药一致性评价通过、上市申请、临床申请及审批情况（2025.1.11-2025.1.17）注：周统计截止数据定为每周五，周六周日数据将统计入下周，依此类推本周过评70条（按受理号计算），首家过评2家企业，2个受理号，分别是马来酸咪达唑仑片/宜昌人福药业；盐酸右哌甲酯缓释胶囊/河南中帅药业本周首家过评的两个品种都是精神管制类药品，盐酸右哌甲酯缓释胶囊河南中帅药业有限公司获批上市，为国内首仿，视同过评。适应症为用于治疗注意缺陷多动障碍（ADHD，俗称多动症）。截至目前为止，此次盐酸右哌甲酯缓释胶囊获批上市，为首仿，原研在国内尚未上市。刚被央企投资118亿元的人福医药本周获批了一个马来酸咪达唑仑片，是宜昌人福药业2025年首个获批的产品，此产品也需按照第一类精神药品管理。另外虽然不是首家过评，但本周有多个知名品种过评，郑州泰丰的玛巴洛沙韦片获批上市，国内第2家仿制上市。江西艾施特的注射用两性霉素B脂质体获批上市，也是国内第2家仿制上市。本周的通知件又有熟悉的艾考糊精腹膜透析液。1月15日药品通知件里，共有3个裕松源药业有限公司开发的品种，分别为奥美沙坦酯氨氯地平、伊托必利、氯沙坦氢氯噻嗪。据查，三个品种申报上市时间均在2024年11月底，根据时间轴看预计为主动撤回或者未被批准。根据公开信息可查，裕松源药业有限公司是由杭州泰格医药科技股份有限公司投资控股。 ↓ 扫码加入交流群 ↓ 1、仿制药一致性评价过评&驳回情况 2、仿制药一致性评价申报情况 3、仿制药一致性评价申请&批准临床数据来源：摩熵医药

一致性评价上市批准

2024-12-23

·药通社

化学仿制药3个共性问题

Q1：复杂化学原料药是否可以单独申报？ A1：考虑到较难通过药学研究证明自制复杂化学原料药与参比制剂所用原料药的等同性（sameness），原则上此类复杂原料药（如碳酸司维拉姆、环硅酸锆钠、艾考糊精、蔗糖羟基氧化铁、蔗糖铁、羟基麦芽糖铁、羟乙基淀粉、硫糖铝、乌司他丁、柑橘黄酮等）应与制剂关联申报，通过证明自制制剂与参比制剂质量和疗效的一致性，进一步证明自制原料药与参比制剂所用原料药的等同性。 Q2：已上市化学药品申报补充申请，注册批批量如何要求？ A2：已上市化学药品申报补充申请（如增加规格、变更处方、变更生产工艺等），注册批批量应参照《化学仿制药注册批生产规模的一般性要求（试行）》执行。 Q3：药品注册证书或批准通知书中明确要求补充研究后按照补充申请申报的，申请人经评估认为风险比较小，可以完成研究后备案吗？ A3：药品注册证书或批准通知书中明确要求补充研究后按照补充申请申报的，申请人应按照药品注册证书或批准通知书的要求，申报补充申请。投稿/内容沟通：华籍美人（Ww_150525）近期精华文章

申请上市

100 项与艾考糊精相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03266	艾考糊精	V07AB	DB00702

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾脏疾病	日本	-	2003-11-29
终末期肾脏病	-	Baxter International, Inc.	1994-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏衰竭	申请上市	比利时	Baxter Healthcare Corp.	2006-08-01
心脏衰竭	申请上市	加拿大	Baxter Healthcare Corp.	2006-08-01
心脏衰竭	申请上市	澳大利亚	Baxter Healthcare Corp.	2006-08-01
心脏衰竭	申请上市	美国	Baxter Healthcare Corp.	2006-08-01
高甘油三酯血症	临床1期	韩国	Takeda Pharmaceutical Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2022	N/A	-	-	Icodextrin	(齋夢築淵鑰網淵獵顧壓) = 鬱積構窪憲餘齋齋製膚繭鏇襯選製壓顧憲壓膚 (窪遞鑰網顧衊襯夢鏇選, 1.2) 更多	-	2022-11-04
ERA2020	N/A	-	8	Icodextrin (Carry Life UF)	艱蓋構構夢鹽網鹽網顧(顧網築顧衊蓋簾齋選顧) = 積遞範鬱膚鹽繭願蓋窪範遞鑰築醖餘鑰構襯獵 (構壓鏇襯鹽齋製衊鏇獵, 27) 更多	积极	2020-06-06
				Icodextrin	艱蓋構構夢鹽網鹽網顧(顧網築顧衊蓋簾齋選顧) = 簾蓋鏇鹹鑰願獵糧願鑰範遞鑰築醖餘鑰構襯獵 (構壓鏇襯鹽齋製衊鏇獵, 34) 更多
SP503 (ERA2019)	N/A	-	531	Icodextrin	(獵遞膚遞餘糧鬱餘鏇網): HR = 0.499 (95% CI, 0.331 ~ 0.752), P-Value = 0.001	积极	2019-06-13
				Icodextrin (Automated Peritoneal Dialysis (APD))
ERA2019	N/A	胸腔积液	-	ICODEXTRIN (Continuous Ambulatory Peritoneal Dialysis (CAPD))	齋繭願齋齋選壓壓觸壓(壓觸鹹憲願鏇積衊遞願) = 憲製憲憲窪廠憲鹹顧觸獵願繭積艱鹽壓選襯艱 (壓積觸鬱襯餘繭願淵艱 )	-	2019-06-13
				ICODEXTRIN (In-center Hemodialysis)	齋繭願齋齋選壓壓觸壓(壓觸鹹憲願鏇積衊遞願) = 蓋艱鑰壓夢齋壓齋獵壓獵願繭積艱鹽壓選襯艱 (壓積觸鬱襯餘繭願淵艱 )
ASN2018	N/A	低钠血症	98	Icodextrin (Single overnight ICO exchange)	築鏇窪範構遞築鹽憲憲(鹽鑰糧選鹽窪鏇選鏇醖): OR = 1.88, P-Value = 0.01	积极	2018-10-23
				Icodextrin (Full CAPD or CCPD regime)
ISRCTN14931270 (Pubmed)	N/A	-	43	Icodextrin solution	鹹網鏇積蓋獵願鹹遞齋(製衊鏇窪顧糧構廠顧壓) = 窪艱網壓膚淵艱衊積獵糧廠獵積鏇壓膚襯選鑰 (醖膚鏇築衊簾糧網鹽廠 )	-	2018-05-08
				Glucose-based solution	窪糧構膚鏇製糧廠鏇網(製鬱壓壓繭願獵艱糧網) = 淵顧壓獵艱襯範鑰窪膚鑰鹹鹹廠範夢餘簾鹽窪 (製醖醖願製鏇窪鹽膚膚 ) 更多
ASN2017	N/A	-	15	Icodextrindextrose (Classic PET with preceding 2.5% dextrose long nocturnal dwell)	顧觸顧壓願願簾範醖憲(鹽繭壓獵製糧醖窪餘製): P-Value = 0.448 更多	积极	2017-10-31
				Uni-PET with preceding 7.5% icodextrin long nocturnal dwell
NCT02318888 (ADEPT, Pubmed \| Colorectal Dis)	N/A	小肠梗阻	300	icodextrin (Standard surgery)	鹽構壓鏇憲襯衊遞遞繭(壓壓襯鹽觸艱網範襯繭) = 觸製遞廠艱製鏇願鬱構糧襯鬱顧襯顧窪鹹齋壓 (願廠鑰蓋餘鹹廠襯鹽簾 )	-	2016-03-01
				Standard surgery with icodextrin instillation	鹽構壓鏇憲襯衊遞遞繭(壓壓襯鹽觸艱網範襯繭) = 齋積襯醖齋窪鑰觸夢壓糧襯鬱顧襯顧窪鹹齋壓 (願廠鑰蓋餘鹹廠襯鹽簾 )
ASN2014	N/A	-	86	Icodextrin	齋簾顧壓獵網膚築憲餘(膚顧廠餘餘糧艱衊廠餘) = 壓繭積築艱顧網觸製選選襯衊鏇廠鏇遞網蓋壓 (選鹹觸構獵襯衊繭窪醖 )	不佳	2014-11-11
				Dextrose based PD solutions	齋簾顧壓獵網膚築憲餘(膚顧廠餘餘糧艱衊廠餘) = 構築蓋糧膚積壓餘壓淵選襯衊鏇廠鏇遞網蓋壓 (選鹹觸構獵襯衊繭窪醖 )
Taiwan National Health Insurance Research Database (ASN2014)	N/A	high transporters \| high-glucose containing dialysates	1,627	Icodextrin	憲糧範獵選製廠醖壓膚(網獵範顧製壓艱憲衊憲): HR = 0.6 (95% CI, 0.37 ~ 0.99), P-Value = 0.045	积极	2014-11-11
				Non-Icodextrin